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ABSTRACT
Background: Diffuse large B-cell lymphoma (DLBCL) has primarily been
treated with cyclophosphamide, doxorubicin, vincristine, and predisone
(CHOP) chemotherapy since the 1970s. Recently, the addition of ritux-
imab to CHOP (CHOP-R) has been found to improve survival and trial-
based results have suggested that it is a cost-effective alternative to CHOP.
Objectives: The objective in this study was to evaluate the cost-
effectiveness of CHOP-R relative to CHOP in ﬁrst-line treatment of
DLBCL in a population-based setting in British Columbia, Canada.
Methods: We created a patient-level simulation model describing poten-
tial pathways for DLBCL patients initiating treatment with either CHOP
or CHOP-R. Model parameters were populated with statistical analyses of
individual-level treatment and effectiveness data and published cost esti-
mates. All results were stratiﬁed by age at treatment initiation (<60 years
vs. 60 years). The base-case scenario was based on a 15-year time
horizon and a 3% discount rate. Probabilistic sensitivity analysis was
performed. All costs are reported as 2006 $CDN.
Results: For the base-case scenario, incremental cost-effectiveness ratios
(ICERs) for younger individuals ranged from $11,965 per disease-free
life-year gained to $19,144 per quality-adjusted life-year gained. For older
individuals, estimated ICERs for all health outcomes were below $10,000
per unit outcome gained for a 15-year time horizon.
Conclusions: Using population-based data, CHOP-R was found to be a
cost-effective alternative to CHOP, particularly for individuals aged 60
years and older. Results from this Canadian observational data source
were consistent with international clinical trial-based studies. The use of
CHOP-R as a ﬁrst-line treatment for DLBCL is recommended, with
respect to both clinical and cost-effectiveness.
Keywords: cost-effectiveness, lymphoma, patient simulation, rituximab.
Introduction
In 2008, there were approximately 7000 new cases of non-
Hodgkin lymphoma diagnosed in Canada with 3100 deaths
attributed to the disease [1]. Diffuse large B-cell lymphoma
(DLBCL) is the most common form of non-Hodgkin lymphoma,
representing approximately 30% of new cases [2].
DLBCL is an aggressive cancer, and before the introduction of
modern treatments survival was typically less than 1 year [3].
Since the 1970s, the most common treatment for DLBCL has
been cyclophosphamide, doxorubicin, vincristine, and predisone
(CHOP) chemotherapy [4]. Approximately 60% of patients
receiving CHOP achieve a complete response in the short term
[5], and approximately 30% of individuals receiving CHOP
achieve long-term cure [6]. Nevertheless, with more than half of
individuals receiving CHOP not cured of their disease, 3-year
progression-free survival is just 44% [7].
Rituximab is a chimeric anti-CD20 immunoglobulin G1
monoclonal antibody that was originally introduced in the mid-
1990s for treating relapsed follicular lymphoma [8]. Since then,
rituximab has been added to CHOP chemotherapy (CHOP-R)
for individuals receiving initial treatment for DLBCL. The efﬁ-
cacy of CHOP-R in this setting has been established via the
Groupe d’Etude des Lymphomes de l’Adulte (GELA) trial [9,10].
Further, an observational study has demonstrated the effective-
ness of CHOP-R in routine practice in British Columbia (BC)
where CHOP-R has been the standard of care for ﬁrst-line
treatment of DLBCL patients since 2001 [11]. Both the GELA
trial and the observational study found a similar risk reduc-
tion for progression-free survival (risk ratios of 0.58 and 0.56,
respectively).
Several theoretical assessments have also found CHOP-R to
be a potentially cost-effective alternative to CHOP for treating
DLBCL, extrapolating from the efﬁcacy results of the GELA trial
[12–15]. The objective in this study was to perform an economic
evaluation of CHOP-R relative to CHOP using actual observa-
tional data describing routine practice in BC. The results of this
study document the relative cost-effectiveness of CHOP-R when
used in actual practice, as opposed to the idealized circumstances
described by a randomized controlled trial.
Methods
Data Sources
Anonymized individual-level data were obtained from the British
Columbia Cancer Agency (BCCA) Lymphoid Cancer Database
which records routinely-collected treatment and outcomes infor-
mation on patients with lymphoid cancer in the Canadian
province of BC. The study sample included 266 HIV-negative
adults (age > 15 years) initiating treatment with CHOP between
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September 1997 and June 2000 and 519 HIV-negative adults
initiating treatment with CHOP-R between March 2003 and
June 2007. Outcomes included relapse, death, or censoring, and
were current to January 2010. All data were irreversibly anony-
mized after extraction from the Lymphoid Cancer Database
before being supplied to study personnel. No study personnel
had access to identiﬁable patient information.
These data were used in several time-to-event analyses to
estimate the distributions associated with time spent in various
health states. Time-to-event analyses included the time from ini-
tiating ﬁrst-line therapy to relapse, and time from initiating
second-line therapy to death. All analyses assumed a parametric
Weibull form for the underlying hazard function.
Per-patient chemotherapy costs were derived from the BCCA
Provincial Systemic Therapy Drug Database from 1995 to 2008,
and these were used to calculate a mean and standard error
associated with each regimen.
The cost of a single radiation fraction was estimated using a
top-down approach, based on the total cost required to fund the
BC radiation therapy program during 2006 to 2007 divided by
the total number of fractions delivered during this time period.
This unit cost was combined with individual-level data describ-
ing the number of fractions received by a patient within a given
treatment regimen to obtain a distribution for radiotherapy costs
for each regimen.
The cost of palliative care was estimated assuming a cost of
$25,000 per year for palliative therapy [16]. This was combined
with the estimated time spent receiving palliative care to obtain
an overall cost distribution.
All other costs were based on a microcosting study of DLBCL
performed in Alberta, Canada [17]. This included costs for
assessment, treatment, and follow-up during ﬁrst-line therapy,
and oncologists, outpatient nursing, tests, hospitalization, and
stem-cell transplantation (SCT) during subsequent regimens. All
costs were stratiﬁed by receipt of rituximab during initial
therapy. All costs are reported as 2006 $CDN.
Utilities were based on those reported by Knight et al. [15],
and were categorized into complete responder (all individuals
currently taking initial therapy and those who respond success-
fully), partial responder (all individuals receiving second-line
therapy with curative intent), and progressive disease (all indi-
viduals receiving palliative care).
Model Structure
The model was structured as a microsimulation, comparing
CHOP versus CHOP-R as ﬁrst-line therapy over a maximum
15-year time horizon. The model was event-based, meaning that
individuals moved forward in time in intervals based on the
timing of certain prespeciﬁed events, rather than in uniform time
cycles [18,19]. The structure of the model is shown in Figure 1.
Potential pathways were determined based on expert opinion,
treatment protocols and empirical data from the BCCA.
The model was evaluated separately for CHOP and CHOP-R
regimens, and for individuals aged 60 years or older versus those
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younger than 60. The time spent receiving a ﬁrst-line regimen
was randomly generated and treatment costs were accumulated
throughout the treatment period. A small number of individuals
were assumed to experience death from toxicity at some point
during the treatment period.
Individuals surviving past the treatment period were then
assigned to one of two outcomes: eventual DLBCL relapse or
eventual mortality from non-DLBCL causes with no prior
relapse. The probabilities associated with the respective out-
comes were dependent on initial treatment regimen and age at
diagnosis (<60 years vs. 60 years).
For individuals who relapsed, time until occurrence of relapse
was randomly generated based on a Weibull survival model.
Separate survival models were ﬁt for the two age categories, so
that the time until relapse was allowed to vary by age. Time
between initial treatment completion and relapse was assumed to
be spent in a “Successful Response” health state. After relapse,
individuals were randomly assigned to one of three second-line
treatment regimens: 1) second-line chemotherapy alone; 2) high-
dose second-line chemotherapy plus SCT; or 3) palliative care.
Each of the second-line treatment regimens was associated with
a corresponding health state and Weibull survival model describ-
ing time between treatment initiation and death. The probability
of receiving a particular second-line therapy was dependent on
age, but for a given therapy the estimated time between therapy
initiation and death was assumed to be independent of age. This
framework was chosen based on empirical data which indicated
an increased probability of palliative care and a decreased prob-
ability of high-dose chemotherapy plus SCT for individuals aged
60 years or older, but no signiﬁcant effect of age within therapy
options. Time until death was then randomly generated for each
individual.
For individuals who were cured or who died of other causes
before relapse, time until death was generated based on age- and
sex-speciﬁc BC life tables [20]. All time between treatment
completion and death was assumed to be spent in the “Successful
Response” state.
Probabilistic sensitivity analysis was performed on all param-
eters of the survival analysis models, as well as the estimated
costs and utilities associated with health states. During each
iteration of the probabilistic sensitivity analysis, new sets of
time-to-event parameters were generated based on the means and
standard errors estimated within the respective Weibull models.
The simulation proceeded based on these randomly generated
model parameters. Costs were generated from gamma distribu-
tions, whereas utilities were estimated from beta distributions.
The method of moments was used to estimate parameters for the
respective gamma and beta distributions based on the mean and
standard errors for costs and utilities.
The health outcomes considered were life-years, quality-
adjusted life-years (QALYs), and disease-free (i.e., preprogres-
sion) life-years. Economic outcomes were deﬁned as the
incremental costs associated with a one-unit improvement in
each of the health outcomes. All costs and outcomes were evalu-
ated both undiscounted and discounted at 3% per year [21]. In
addition, we performed a one-way sensitivity analysis using a
maximum time horizon of 5 years, reﬂecting the period of
empirical data availability.
Assumptions
In addition to high-level assumptions regarding model structure
and appropriate parametric form for survival analyses, several
assumptions were made regarding key model parameters in the
base-case analysis.
Because of the limited period of availability of rituximab, only
6-year follow-up data were available for CHOP-R, and assump-
tions were required regarding long-term relapse and cure rates. As
an upper bound for the cure rate after CHOP-R treatment, it was
assumed that all the relapses after CHOP-R treatment were
observed within the 6 years of follow-up data that were available.
This is consistent with the cure rate after CHOP as the large
majority (>80%) of relapses in the CHOP group occurred within
5 years. The lower bound for the CHOP-R cure rate was assumed
to be equivalent to the CHOP cure rate. During the probabilistic
sensitivity analysis, the CHOP-R relapse rate was varied between
these two extremes using a uniform distribution.
After second-line therapy, no data were available describing
date of further refractory or relapsed disease or receipt of pallia-
tive treatment. We therefore made the simplifying assumption
that all deaths occurring within 3 years of relapse were due to
lymphoma, whereas all deaths occurring more than 3 years after
relapse were due to other causes. This assumption was based on
empirical data showing that the Kaplan–Meier curve had reached
a ﬂat plateau within 3 years of relapse, and was veriﬁed by
clinical experts in lymphoma. Deaths due to lymphoma were
assumed to be associated with end-of-life costs equal to average
palliative care costs, whereas deaths associated with other causes
were not associated with palliative care costs.
Results
Of the 785 individuals included in the observational data source,
45.3% were younger than 60 years old at time of DLBCL diag-
nosis. This distribution was relatively constant over time, with
47.7% younger than age 60 during the pre–rituximab era and
44.1% younger than age 60 during the post–rituximab era.
The average costs associated with ﬁrst- and second-line
therapy are given in Table 1. The costs for ﬁrst-line therapy
reﬂect the costs associated with an entire course of therapy,
including medications, assessment, follow-up, oncologists,
nursing, laboratory tests, and hospitalizations. The probability of
receiving radiotherapy was varied by treatment regimen and age
category, but, conditional on receiving radiotherapy, the associ-
ated cost per radiotherapy course was assumed to follow a con-
stant distribution across treatment regimens. In the BCCA data,
the percentage of patients receiving radiotherapy was 37% for
both CHOP and CHOP-R for individuals younger than age 60
and 25% for older individuals. Across age categories and options
for second-line therapy, the percentage of individuals receiving
radiotherapy varied between 21% and 41%.
The probabilities of all health state transitions and the time
distributions associated with the various health states are sum-
marized in Table 2. After initiating ﬁrst-line therapy, the poten-
tial transitions were to: death from toxicity of ﬁrst-line
treatment, relapse/progression, or death from non-lymphoma-
related causes. Therefore, all individuals who did not experience
progressive disease or toxicity-related death were assumed to
eventually die of other causes. After all of the second-line therapy
options, the only subsequent health state considered was death so
that 100% of individuals eventually transitioned to the death
state. Nevertheless, there was variability across treatment
options and individuals as to when this transition would occur
and whether or not it would be due to lymphoma-related causes.
It was assumed that survival after second-line therapy was inde-
pendent of receipt of rituximab in initial therapy regimen.
Figure 2a,b shows the estimated time until relapse after ﬁrst-
line therapy for individuals younger than age 60 years and 60 or
older, respectively. The available data provided approximately
6-year follow-up for patients receiving CHOP-R, at which point
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61% of younger CHOP-R patients and 68% of older CHOP-R
patients are projected to remain free from relapse. More than 10
years of follow-up data were available for patients receiving
CHOP, with 50% of younger CHOP patients and 29% of older
CHOP patients projected to remain free from relapse at the end
of follow-up. It was therefore assumed in the simulation model
that the cure rate for CHOP was 50% for individuals younger
than 60 and 29% for individuals aged 60 or older, whereas the
cure rate for CHOP-R was varied uniformly between 50% and
61% for younger individuals and 29% and 68% for older indi-
viduals in the probabilistic sensitivity analysis.
The estimate of a 61% upper bound for cure rate for younger
CHOP-R patients is based on an empirically observed sudden
increase in relapse at 6 years (Fig. 2a). Nevertheless, this increase
was heavily inﬂuenced by a single death because of the small
number of patients providing follow-up to this point. The 95%
CI for 6-year relapse-free survival was 42% to 89%, with the
width reﬂecting the small remaining sample size. The estimated
cure rate at 5 years was 74% with a substantially narrower 95%
CI of 67% to 80%, and is likely a more reliable estimate of the
actual cure rate. Nevertheless, our base-case analysis used a
maximum cure rate of 61%, which provides a more conservative
estimate of CHOP-R efﬁcacy and will result in CHOP-R appear-
ing less favorable. We also performed a sensitivity analysis in
which we assumed that the maximum cure rate for younger
individuals receiving CHOP-R was 74%.
For patients younger than 60 who relapsed, the second line of
therapy was: chemotherapy with curative intent (no SCT) for
37% of patients; high-dose chemotherapy and SCT with curative
intent for 19% of patients; and palliative care in the remaining
44% of patients. For older patients, second-line therapy con-
sisted of: chemotherapy for 15%; high-dose chemotherapy with
SCT for 3%; and palliative care for 82%. For the chemotherapy
and high-dose chemotherapy with SCT regimens, the average
cost reported reﬂects the cost for the entire course of therapy,
including the same components as for ﬁrst-line therapy. For the
palliative therapy options, the average cost is the estimated cost
per year spent receiving palliative therapy (16), and, for each
patient receiving a palliative regimen, the cost per year was
multiplied by the randomly-generated number of years that they
spent in the palliative health state.
Figure 3 shows the estimated time until death after relapse for
the three possible options of second-line therapy. These analyses
were restricted to patients who relapsed after ﬁrst-line therapy,
and who initiated a second round of treatment. Time was mea-
sured relative to start date of second-line therapy. Based on
empirical analyses, these curves were assumed to apply to indi-
viduals of all ages.
Health outcome and cost-effectiveness results are given in
Table 3a,b. With a 15-year time horizon and a 3% discount rate,
incremental cost-effectiveness ratios (ICERs) for younger indi-
viduals ranged from $11,965 per disease-free life-year gained to
$19,144 per QALY gained. The corresponding range for undis-
counted results was $10,632 per disease-free life-year gained to
$15,948 per QALY gained. When the time horizon was restricted
to 5 years, the estimated ICERs were $48,320 per life-year gained
and per QALY gained, and $32,213 per disease-free life-year
gained. This increase in ICERs approaching standard cost-
Table 1 Input costs assumed for ﬁrst- and second-line therapy in diffuse large B-cell lymphoma
Regimen
Estimated cost
(standard error)
Probability of radiation Radiation cost per
course (standard error)*<60 years 60 years
First line $5,773 ($166)
CHOP-R (per course)* $33,968 ($1,979) 0.37 0.25
CHOP (per course)* $22,727 ($3,477) 0.37 0.25
Second line
Chemotherapy (per course)* $20,920 ($4,164) 0.41 0.25
Chemotherapy + SCT (per course)* $31,957 ($6,590) 0.21 0.00
Palliative (per year)† $25,000 ($7,500) 0.33 0.28
*Source(s): Lee et al. [17]; BC Cancer Agency. Includes treatment, assessment, and follow-up (medications, oncologists, nursing, tests, hospitalization).
†Source(s): Fassbender et al. [16].
CHOP, cyclophosphamide, doxorubicin, vincristine, and predisone; CHOP-R, CHOP with rituximab; SCT, stem-cell transplantation.
Table 2 Probabilities and mean times associated with health state transitions
Health state transition
CHOP-R CHOP
Probability of transition
Mean time (years)
(95% CI) Probability of transition
Mean time (years)
(95% CI)
First line
First-line therapy <60 years 0.008 0.36 (0.27–0.45) <60 years 0.008 0.31 (0.21–0.40)
→ Toxicity death 60 years 0.026 60 years 0.026
First-line therapy <60 years 0.39–0.50* 0.93 (0.69–1.16) <60 years 0.50 0.81 (0.60–1.02)
→ Relapse 60 years 0.32–0.71* 0.72 (0.55–0.90) 60 years 0.71 0.88 (0.66–1.10)
Second line
Second-line chemotherapy 1.00 1.94 (1.02–2.86) As for CHOP-R patients
→ Death
High-dose chemotherapy + stem-cell transplantation 1.00 5.49 (2.42–8.56)
→ Death
Palliative care 1.00 0.43 (0.33–0.54)
→ Death
*Varied randomly across probabilistic sensitivity analysis.
CHOP, cyclophosphamide, doxorubicin, vincristine, and predisone; CHOP-R, CHOP with rituximab.
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effectiveness thresholds [22] reﬂects the fact that the majority of
costs occurs in the ﬁrst 5 years, whereas beneﬁts in outcome
extend into subsequent years. For older individuals, ICERs were
more favorable: estimated ICERs for all health outcomes were
below $10,000 per unit outcome gained when using a 15-year
time horizon. With a 5-year time horizon, estimated ICERs for all
health outcomes remained below $20,000 per unit outcome
gained.
When the upper bound of the cure rate for CHOP-R in
younger individuals was increased to 0.74 from 0.61, all esti-
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Figure 2 Time until relapse or cure after ﬁrst-line
therapy with cyclophosphamide, doxorubicin, vinc-
ristine, and predisone (CHOP) and CHOP with
rituximab (CHOP-R) for diffuse large B-cell lym-
phoma, for patients (a) <60 years and (b) 60
years.
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mated ICERs dropped accordingly: $8325 per life-year gained,
$10,174 per QALY gained, and $7044 per disease-free life-year
gained. This sensitivity analysis was based on a time horizon of
15 years and a discount rate of 3%.
Results of the probabilistic sensitivity analysis are shown in
Figure 4a,b for the base-case scenario of a 15-year time horizon
and 3% discounting. Assuming a willingness-to-pay (WTP)
threshold of $50,000 per QALY, CHOP-R was found to be
cost-effective in 68% of iterations for younger individuals and
73% of iterations for older individuals.
Discussion
In this study, we found CHOP-R to be a cost-effective alternative
to CHOP for ﬁrst-line therapy in diffuse large B-cell lymphoma.
The economic evaluation was based on “real-life” use of
CHOP-R using data from a large observational cohort, thus
conﬁrming the results from other theoretical models. We applied
a microsimulation model that generated individual life histories
for hypothetical lymphoma patients receiving CHOP or
CHOP-R as initial therapy.
One limitation to our study was the use of historical controls.
Because CHOP-R was introduced as standard care for ﬁrst-line
DLBCL treatment in BC in 2001, there was no contemporary
control group available for comparison, and DLBCL patients
from 1997 to 2000, who received CHOP, formed the control
group. Nevertheless, we expected minimal bias from the use of
historical control data, as, with the exception of the addition of
rituximab to initial therapy, all aspects of DLBCL diagnosis and
treatment have remained consistent over the study period. These
aspects include: diagnosis methods and criteria, disease staging,
supportive care elements, and treatment retention. This is further
supported by the fact that the results of observational studies
using historical controls to compare CHOP and CHOP-R have
produced results that are consistent with prospective randomized
controlled trials [9,11].
Several other economic analyses comparing CHOP-R with
CHOP have been performed in other countries [12–15].
Although all these studies found CHOP-R to be a cost-effective
therapy based on standard WTP thresholds, there was variability
between ICERs. Speciﬁcally, the base case cost per QALY gained
was estimated to be $16,400 in France [12], $15,100 to $20,100
in The Netherlands [13], $23,500 in the United States [14], and
$13,900 to $19,600 in the UK (all currencies converted to 2006
Canadian dollars using health-speciﬁc purchasing power parities
[23]) [15]. Examination of cost and QALY results individually
suggests that the variability in these results is driven almost
entirely by differences in cost estimates, as the health outcomes
were similar across all studies. Although this study is based on
observational data compared to other published economic evalu-
ations based on clinical trial data, differences in estimated life-
years and QALYs tended to be minor enough to be likely
explained by differences in study populations, speciﬁc treatment
protocols, and assumptions regarding long-term survival. Con-
versely, total cost estimates varied more than threefold across
studies for the CHOP arm and more than twofold for the
CHOP-R arm [13,15]. The BC cost estimates presented here are
within the range of those found in other studies for both arms,
although incremental differences between arms tended to be
smaller here compared with those reported in other studies,
leading to generally smaller ICERs. Potential sources for cost
differences include different acquisition costs for rituximab, dif-
ferent distributions among second-line therapy options, different
costs associated with second-line therapy, or methodological dif-
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ferences such as speciﬁc components of direct medical costs
included. This variability highlights the importance of repeating
economic evaluations for different health systems, as different
funding structures could potentially lead to different conclusions
in terms of cost-effectiveness.
Conclusion
Using a microsimulation built from observational Canadian
data, CHOP-R was found to be a cost-effective alternative to
CHOP chemotherapy alone for ﬁrst-line treatment of DLBCL.
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Figure 4 Scatterplot of incremental costs and
beneﬁts estimated using probabilistic sensitivity
analysis for base-case scenario of 3% discount rate
and 15-year time-horizon, for patients (a) <60
years and (b) 60 years.WTP, willingness to pay;
QALY, quality-adjusted life-year.
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The cost-effectiveness was most pronounced in individuals aged
60 and older because of improved effectiveness of CHOP-R
observed in this age group. Results reported here are qualitatively
consistent with studies performed in other jurisdictions using
clinical trial data, in which CHOP-R was also found to be
cost-effective based on standard WTP thresholds. Thus, all eco-
nomic analyses performed to date support current practice guide-
lines in BC regarding the provision of CHOP-R as standard
ﬁrst-line therapy in DLBCL patients.
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